Skoglund, Charlotte
Leknes, Siri
Heilig, Markus
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 6 September 2020
Accepted: 11 March 2022
First Online: 15 April 2022
Declarations
:
: A protocol for this was developed and approved by the Swedish Ethics Authority (dnr. 2019-05335).
: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
: CS is the founder and owner of Smart Psykiatri, a private clinic contracted by Swedish publicly-financed healthcare for assessment and treatment of ADHD. She has served as invited speaker for Shire, Nordic Drugs, Takeda, Evolan, DNE Pharma, Novartis UK, UCD, Gedeon Richter, Medice Nordic Norway, and Principal Investigator GODDESS study by Takeda 2021-2022 CS is a member of the Scientific Council at the Swedish Medical Products Agency SE-75103 Uppsala Sweden. The views expressed in thispaper are not necessary the view of the Government agency.